Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for Radiation-induced Lung Injury
NCT02296281Phase 2Unknown
- Sponsor
- Gyre Pharmaceuticals
- Start
- Jan 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of pirfenidone in radiation-induced lung injury (RILI), sponsored by Gyre Pharmaceuticals. Status: unknown.
02
Drugs
pirfenidone
03
Conditions
radiation-induced lung injury (RILI)
Beyond the preview
Go deeper on NCT02296281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296281.